Shares of Glenmark Pharmaceuticals Ltd soared 3% on 3 March after the company announced acquiring and launching Acetylcysteine injection in the United States through its subsidiary. 

Glenmark is set to introduce its new Acetylcysteine Injection in the U.S. market in a 6 gm/30 mL (200 mg/mL) strength, available in single-dose vials, further expanding its injectable product portfolio.

This newly launched injection is designed to provide the same therapeutic benefits as Acetadote Injection (6 gm/30 mL, 200 mg/mL), a branded drug manufactured by Cumberland Pharmaceuticals Inc., Glenmark informed the stock exchanges.

Acetylcysteine is widely used for treating acetaminophen overdose and as a mucolytic agent to manage respiratory conditions.

The U.S. Food and Drug Administration (FDA) approved Glenmark’s version based on the established safety and efficacy data of Acetadote Injection.

Glenmark acquired the Abbreviated New Drug Application (ANDA) for this Acetylcysteine Injection from Aspen Pharma USA Inc., aiming to offer a cost-effective and reliable alternative in the market.

According to IQVIA sales data for the 12 months ending January 2025, Acetadote Injection recorded annual sales of approximately $15.2 million in the U.S. market.

At 3:30 pm, the shares of Glenmark Pharma were trading 3.00% higher at 1,317.35 on NSE.

Ask the analyst & get instant answer about Glenmark Pharmaceuticals Ltd.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!